Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.

[1] Trazodone is an old second-generation antidepressant with strong sedative activity, widely used as a hypnotic drug in subtherapeutic antidepressant doses of 100 mg or less, although the ...

Teva Pharmaceutical Industries Limited has a 12-month low of $11.83 and a 12-month high of $22.80. The stock has a market capitalization of $19.07 billion, a PE ratio of -11.61, a price-to ...

2025 Free Cash Flow Guidance: $1.6 billion to $1.9 billion. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 9% increase in revenue for 2024, reaching $16.5 billion, driven by strong ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands among ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares opened today at $17.99. According to TipRanks ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $30.00. The company’s shares ...

Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus TEVA. And retail traders should know. We noticed this today when the trades showed up on publicly ...